Ind-Swift Laboratories (NSE:INDSWFTLAB) Other Current Liabilities: ₹1,032 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:INDSWFTLAB Ind-Swift Laboratories Ltd NSE:INDSWFTLAB
48 GF Score
Price ₹229.86
GF Value ₹36.76
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Ind-Swift Laboratories Other Current Liabilities?

Ind-Swift Laboratories NSE:INDSWFTLAB -3.30% 48 Other Current Liabilities is ₹1,032 Mil as of Mar. 2026. GuruFocus rates NSE:INDSWFTLAB with a GF Score™ of 48/100 and a GF Value™ of ₹36.76 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Ind-Swift Laboratories's other current liabilities for the quarter that ended in Mar. 2026 was ₹1,032 Mil.

Ind-Swift Laboratories's quarterly other current liabilities declined from Sep. 2025 (₹696 Mil) to Dec. 2025 (₹0 Mil) but then increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹1,032 Mil).

Ind-Swift Laboratories's annual other current liabilities declined from Mar. 2024 (₹1,155 Mil) to Mar. 2025 (₹308 Mil) but then increased from Mar. 2025 (₹308 Mil) to Mar. 2026 (₹1,032 Mil).

Ind-Swift Laboratories Other Current Liabilities Related Terms

Ind-Swift Laboratories Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Ind-Swift Laboratories's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ind-Swift Laboratories Other Current Liabilities Chart

Ind-Swift Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 409.20 305.49 1,154.67 308.16 1,031.57

Ind-Swift Laboratories Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 308.16 696.16 0.00 1,031.57
NSE:INDSWFTLAB
48GF Score
Ind-Swift Laboratories Ltd NSE:INDSWFTLAB
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ind-Swift Laboratories Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of ₹1,032 Mil mean?
Ind-Swift Laboratories (NSE:INDSWFTLAB) has a Other Current Liabilities of ₹1,032 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Ind-Swift Laboratories.
Is Ind-Swift Laboratories' Other Current Liabilities too high?
Ind-Swift Laboratories' current Other Current Liabilities is ₹1,032 Mil. Overall, Ind-Swift Laboratories has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ind-Swift Laboratories' Other Current Liabilities compare to ZTS and UTHR?
Ind-Swift Laboratories' Other Current Liabilities of ₹1,032 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Drug Manufacturers company?
A good Other Current Liabilities depends on the Drug Manufacturers industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Ind-Swift Laboratories. Ind-Swift Laboratories's current Other Current Liabilities is ₹1,032 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ind-Swift Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Ind-Swift Laboratories (NSE:INDSWFTLAB) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹36.76, compared to a current price of ₹229.86 — trading 525.3% above its estimated fair value. The current Other Current Liabilities is ₹1,032 Mil. Ind-Swift Laboratories' overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Ind-Swift Laboratories (NSE:INDSWFTLAB), the current Other Current Liabilities is ₹1,032 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ind-Swift Laboratories (NSE:INDSWFTLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Ind-Swift Laboratories stock appears to be overvalued. The current stock price of ₹229.86 is trading 525.3% above its estimated GF Value™ of ₹36.76. GuruFocus considers Ind-Swift Laboratories to be Significantly Overvalued.

Key valuation signals for NSE:INDSWFTLAB:

  • Other Current Liabilities: ₹1,032 Mil
  • GF Value™: ₹36.76 vs. price of ₹229.86 (525.3% above fair value)
  • GF Score™: 48/100 with 4 warning signs

No single metric tells the full story. See the NSE:INDSWFTLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ind-Swift Laboratories Business Description

Other Exchanges 532305:India
Address SCO 850, NAC, Shivalik Enclave, Manimajra, Chandigarh, PB, IND, 160101
Ind-Swift Laboratories Ltd is involved in manufacturing Active Pharmaceutical Ingredients (API), Intermediates, and formulations. The company serves various therapeutic segments, including Cardiovascular health, Antihistamines, Antidiabetics, Antipsychotics, Parkinson's disease, Antineoplastics, ADHD Symptoms, Analgesics, Alcohol Abstinence, and Bone Resorption Inhibitors. It operates solely in the pharmaceutical products sector. Geographically, the company supplies both domestic and international markets, with the majority of its revenue coming from outside India.
48GF Score

Get the complete analysis for NSE:INDSWFTLAB

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹229.86
Price
₹36.76
GF Value